Read More Greg Baker, Ph.D., is the Director of Business Development for the Technology & Innovation Development Office (TIDO) at Boston Children’s Hospital.

Greg’s role at TIDO is to help commercialize technologies developed at Boston Children’s Hospital. Greg works with the licensing team and the faculty at all stages of the innovation life cycle, from conception to the transition to the marketplace. He draws upon his experience in technology commercialization at academic institutions such as Children’s National in Washington D.C. and Children’s Hospital of Philadelphia, as well as business development roles at Novartis and Syngenta. His experience also includes supporting startup companies during their initial formation and with competing for early-stage funding, and he is also a registered patent agent.

Greg’s business experience supplements his scientific training of an undergraduate degree in Microbiology from the University of California, San Diego, and a PhD in Molecular Genetics from Harvard Medical School.

Greg joined BCH in February 2021, and he is excited to be part of the TIDO team.
Read Less

Read More Leslie S. Kean, MD PhD, is a clinician-scientist with extensive laboratory and clinical expertise in transplantation and translational immunology. She is the Director of Pediatric Stem Cell Transplant at Boston Children’s Hospital and the Dana-Farber Cancer Institute, and is the Stranahan Professor of Pediatrics at Harvard Medical School. She is the Chair of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC). Dr. Kean’s research program is focused on the immunology of hematopoietic stem cell transplantation and immune tolerance in allo- and auto-immune diseases. The overarching goal of her research is to understand mechanisms underlying immune tolerance, with a specific focus on mixed-chimerism induction for solid organ transplantation, graft-versus-host disease (GvHD), transplant rejection, the immunology of GI auto-immune diseases, and the reconstitution of protective immunity after transplantation. Dr. Kean’s work has led to the creation of multiple novel, MHC-defined non-human primate models of both engraftment and GvHD and to several first-in-disease clinical trials.
Read Less

Read More Joseph A. Majzoub attended the University of Michigan Honors College and Stanford University School of Medicine. These were followed by internship, residency, and chief residency at the Peter Bent Brigham Hospital, and a postdoctoral fellowship in endocrinology at the Massachusetts General Hospital and the Massachusetts Institute of Technology. Dr. Majzoub joined the Division of Endocrinology at the Brigham and Women's Hospital in 1981, where he remained until moving to Boston Children’s Hospital in 1989 as Chief of the Division of Endocrinology, a position he held for over 29 years until stepping down in 2018 to become the Vice Chair for Research in the Department of Pediatrics. Dr. Majzoub is the Thomas Morgan Rotch Professor of Pediatrics and Professor of Medicine at Harvard Medical School. Dr. Majzoub’s research concerns how stress influences health and disease, with a particular interest in diseases of the adrenal axis and obesity. He is the scientific founder of three biotech companies focused in molecular diagnostic, therapeutic, and genetic engineering domains. Dr. Majzoub is a mentor to many medical students, postdoctoral fellows, and faculty throughout the United States, and has received several teaching and mentoring awards from Boston Children's Hospital, Harvard Medical School and the Harvard-MIT Health Sciences Technology Program.
Read Less

Read More Michael Foley, Ph.D., is Chief Executive Officer for Deerfield Discovery and Development, and Vice President of Translational Drug Development at Deerfield. Dr. Foley joined Deerfield in 2018 to focus on academic collaborations. Most recently, he was the CEO and Sanders Director at Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) where he led the efforts to discover drug candidates in an academic setting. Prior to Tri-I TDI, he was Director of the Chemical Biology Platform at the Broad Institute of MIT and Harvard. Dr. Foley is the founder and a director of Forma Therapeutics. In 2001, he founded Infinity Pharmaceuticals and in 2000, he founded CombinatoRx. In 1999, he was a founding member of the Harvard Institute of Chemistry and Cell Biology and served as the head of Chemical Technology. He was a GlaxoSmithKline Fellow at Harvard University and previously a Research Chemist at GlaxoSmithKline. Dr. Foley began his career at Bristol-Myers Squibb as a Research Chemist. He received his B.S. from St. Norbert College, his M.S. from Utah State University and his Ph.D. from Harvard University.
Read Less

Read More William Slattery is a Partner on the Therapeutics team and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for 10 years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.
Read Less

Read More Mei-Mei joined the Technology and Innovation Development Office (TIDO) of Boston Children’s Hospital in July 2017 as an Entrepreneur-in-Residence, with the mission of helping Boston Children’s Hospital’s Principle Investigators to build new ventures using their relatively mature technologies.

Mei-Mei has 18+ years of experience working in pharmaceutical and biotech industry. She has held key functions in multiple areas, including project management, operations and business development & licensing. Mei-Mei obtained her PhD in molecular biology at University of Southern California and MBA at University of California at Los Angeles.
Read Less

Read More Sabrina joined the Technology and Innovation Development Office (TIDO) of Boston Children’s Hospital in January 2021. As a Strategic Alliance Manager, she is responsible for building and managing alliances with external partners and internal stakeholders.

Prior to joining TIDO, Sabrina was a Business Development Manager at Ximbio (part of Cancer Research UK). During her time at Ximbio, Sabrina built new partnerships with academic and research institutions in the US, Canada, and Puerto Rico and evaluated research tools for licensing and commercialization. Sabrina received her Ph.D in Pharmacology from the University of Washington and completed her Technology Entrepreneurial Certificate through the Foster School of Business. During her graduate career, Sabrina received a summer fellowship with ITHS/WRF Capital. Sabrina was involved in Seattle life science community, including service as member for the Life Science and Global Health Workforce Panel of the Washington State Governor’s Office.
Read Less